Endoglin Targeting: Lessons Learned and Questions That Remain.

Area of Science:

• Molecular Biology
• Oncology
• Immunology

Background:

• Endoglin (CD105) functions as a transforming growth factor-beta (TGF-β) coreceptor, vital in development and tumor angiogenesis.
• High endoglin expression on tumor vasculature correlates with poor patient survival, identifying it as a potential cancer therapeutic target.

Purpose of the Study:

• To review preclinical data, clinical trials, and biomarker studies of the endoglin-neutralizing antibody TRC105 (Carotuximab).
• To elucidate the role of endoglin in angiogenesis and its function within the tumor microenvironment.
• To assess the therapeutic potential of targeting endoglin in cancer treatment.

Main Methods:

• Comprehensive review of preclinical cancer models evaluating TRC105 efficacy.
• Analysis of Phase I-III clinical trial data for TRC105 as monotherapy and in combination regimens.
• Examination of biomarker studies to understand endoglin expression and function.

Main Results:

• TRC105 demonstrated activity in various preclinical cancer models.
• Clinical studies provided insights into TRC105's safety, efficacy, and optimal use in combination therapies.
• New understanding of endoglin's broader role in the tumor microenvironment beyond angiogenesis.

Conclusions:

• TRC105 (Carotuximab) represents a promising therapeutic strategy targeting endoglin in cancer.
• Further research is needed to fully understand endoglin's multifaceted roles and optimize TRC105 treatment strategies.
• Biomarker studies are crucial for patient selection and predicting response to endoglin-targeted therapies.